本帖最后由 老马 于 2013-3-13 13:43 编辑
+ J/ u ^$ h6 }* U, x( Y" k4 D4 v, ^$ p7 [
健择（吉西他滨）+顺铂+阿瓦斯汀: o& z7 X% s4 B# C8 o) m
Gemzar +Cisplatin + Avastin
O3 d% G1 @/ N7 y9 P, Lhttp://annonc.oxfordjournals.org/content/21/9/1804.full
9 O( R% ^$ w; l* Z7 m$ VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) % n v( J# I, }0 ?3 X
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ( W( k+ |3 Z' P2 Z4 T/ P! b
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ' `! ~; z2 W9 \7 J# m" H+ J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 629)
5 G' ^( j- O4 i
华为网盘附件：
2 B/ b- ]' i3 D- q! |: }【华为网盘】ava.JPG9 |+ B, G) V$ J
|
显身卡
